<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02277574</url>
  </required_header>
  <id_info>
    <org_study_id>AMP-110-02</org_study_id>
    <nct_id>NCT02277574</nct_id>
  </id_info>
  <brief_title>Assess Safety, Tolerability, Pharmacokinetics and Clinical Activity of AMP-110 in Subjects With Rheumatoid Arthritis</brief_title>
  <official_title>A Randomized, Multi-Dose, Placebo-Controlled, Study of the Safety, Tolerability, Pharmacokinetics and Clinical Activity of AMP-110 in Subjects With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b, randomized, multi-dose, placebo-controlled, dose-escalation, multi-center
      study of AMP-110 in adult subjects with rheumatoid arthritis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acceptable number of adverse events per subject as a measure of safety and tolerability of repeat doses of AMP-110 versus placebo</measure>
    <time_frame>From start of study drug administration through Day 112</time_frame>
    <description>Determined by the number of AEs, SAEs, and results in laboratory evaluations, vital signs, electrocardiograms and physical examinations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Repeat dose pharmacokinetic parameters of AMP-110 in serum</measure>
    <time_frame>From start of study drug administration through Day 112</time_frame>
    <description>Parameters will include maximum observed concentration (Cmax), area under the concentration-time curve (AUC), total body clearance and terminal half-life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Optimal dose for repeat dosing of AMP-110</measure>
    <time_frame>From start of study drug administration through Day 112</time_frame>
    <description>Optimal dose will be determined through the occurrence of AEs, SAEs, ACR-20 and DAS-28 results, and individual AMP-110 concentrations in serum including peak and trough levels</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Clinical responses via RA disease scoring systems</measure>
    <time_frame>From start of study drug administration through Day 112</time_frame>
    <description>Explore the pharmacodynamics (PD) of repeat doses of AMP-110 versus placebo in subjects with RA</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Crossover Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects assigned to this arm will receive 1 of 3 escalating doses of AMP-110 once a week for 4 weeks followed by 4 weekly doses of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects assigned to this arm will receive 4 weekly doses of placebo followed by 1 of 3 escalating doses of AMP-110 once a week for 4 week</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AMP-110</intervention_name>
    <description>2, 5, or 10 mg/kg</description>
    <arm_group_label>Crossover Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Crossover Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be able to provide written informed consent

          -  Body mass index 18.5 to 35.0 kg/m2

          -  Diagnosis of Rheumatoid Arthritis according to 1987 revised American College of
             Rheumatology (ACR) criteria

          -  Global Functional Class I, II, or III according to ACR 1991 revised criteria

          -  Must have at least 4 tender joints and 4 swollen joints (28-joint assesssment)

          -  Use of &gt;/= 1 non-steroidal anti-inflammatory drugs is allowed, subject must be on a
             stable dose for &gt;/= 2 weeks prior to randomization

          -  Use of &gt;/= 1 Disease Modifying Anti-rheumatic Drugs (DMARD) for &gt;/= 3 months and a
             stable dose for &gt;/= 6 weeks prior to randomization

          -  Stable use of low dose oral corticosteroids (&lt;/= 10 mg prednisone per day or
             equivalent) is allowed; subjects must be on a stable dose for &gt;/= 4 weeks prior to
             randomization

        Exclusion Criteria:

          -  Prior to Day 0, use of:

               1. Rituximab within 6 months

               2. Abatacept within 3 months

               3. Infliximab, Adalimumab, Certolizumab, Tocilizumab, Cyclosporine, Azathioprine or
                  Mycophenolate mofetil within 2 months

               4. Etanercept, Anakinra, immunoglobulin or blood products within 28 days

               5. Prior immunotherapy, including high dose oral corticosteroids or systemic
                  corticosteroids such as prednisone, biologics, Janus kinase (JAK) inhibitors,
                  such as tofacitinib or investigational therapy must have completed at least 5
                  half-lives or 30 days, whichever is longer

               6. Prior exposure to T cell depleting agents such as Campath (alemtuzumab)

          -  Evidence of any active or recent infection

          -  History of systemic autoimmune disease other than Rheumatoid Arthritis; secondary
             Sjogren's syndrome, rheumatoid vasculitis and orther extra-articular manifestations of
             RA allowed

          -  History of allergic reactions

          -  History of anaphylaxis or allergic diathesis

          -  Clinically significant cardiac disease, including: unstable angina; myocardial
             infarction within 6 months; congestive heart failure; arrhythmia requiring active
             therapy, with the exception of clinically insignificant extrasystoles, or minor
             conduction abnormalities; and history of clinically significant abnormality on
             electrocardiogram

          -  Evidence of active or latent tuberculosis

          -  Vaccination with live attenuated viruses within the 2 weeks prior to Day 0

          -  Pregnant or breastfeeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pinnacle Research Group, LLC</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Research Consultants, LLC.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Center, Inc.</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Treatment Center</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physician Research Collaboration, LLC</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metroplex Clinical Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2014</study_first_submitted>
  <study_first_submitted_qc>October 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2014</study_first_posted>
  <last_update_submitted>November 17, 2016</last_update_submitted>
  <last_update_submitted_qc>November 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>Arthritis</keyword>
  <keyword>Joint diseases</keyword>
  <keyword>Musculoskeletal diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

